TNXP Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
EN
07/10/2020

Underlying

TNXPTonix Pharmaceuticals Holding Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tonix Pharmaceuticals Holding Corp

 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for ...

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CHATHAM, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today an...

September 18, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclona...

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase 2/3 study Approximately 70 million people that are eligible for treatment live in areas of the U.S. in which Lyme Disease is endemic CHATHAM, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutic...

September 17, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatm...

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025 Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo Tonmya showed consistent improvements across core fibromyalgia symptoms, including widespread pain, sleep disturbance and fatigue Tonmya was well tolerated, supporting its potential as a long-term treatment option for fi...

September 8, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor ...

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Tonix’s Chief Executive Officer, will be participating in a fireside chat at the 2025 Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025 at 1:35 PM ET. A webcast of the fireside chat will be av...

August 28, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzapri...

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monda...

August 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch